AzurRx BioPharma Inc News - AZRX

Proxy Statement (definitive) (def 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark...

Current Report Filing (8-k)

false 0001604191 0001604191 2021-11-09 2021-11-09 UNITED STATES SECURITIES AND EXCHANGE...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy...

Current Report Filing (8-k)

false 0001604191 0001604191 2021-11-04 2021-11-04 UNITED STATES SECURITIES AND EXCHANGE...

Current Report Filing (8-k)

0001604191false00016041912021-09-272021-09-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares UNITED...

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or...

Current Report Filing (8-k)

0001604191false00016041912021-09-142021-09-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares UNITED...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three...

Current Report Filing (8-k)

0001604191false--12-3100016041912021-09-102021-09-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares UNI...

AzurRx BioPharma Announces Reverse Stock Split

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”...

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned...

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

AzurRx BioPharma Inc (AZRX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

AZRX News

Proxy Statement (definitive) (def 14a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Current Report Filing (8-k)

Current Report Filing (8-k)

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

Current Report Filing (8-k)

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

Current Report Filing (8-k)

AzurRx BioPharma Announces Reverse Stock Split

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

AZRX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

AzurRx BioPharma Inc (AZRX) News

AzurRx BioPharma Inc (AZRX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

AZRX News

Proxy Statement (definitive) (def 14a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Current Report Filing (8-k)

Current Report Filing (8-k)

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

Current Report Filing (8-k)

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

Current Report Filing (8-k)

AzurRx BioPharma Announces Reverse Stock Split

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

AZRX Discussion

Your Recent History